1. Земцовский Э.В. Диспластические фенотипы и диспластическое сердце. Аналитический обзор. - СПб.: Изд-во «Ольга», 2007. - 80 с.

2. Ades L. CSANZ cardiovascular genetics working group. Guidelines for the diagnosis and management of Marfan syndrome // Heart Lung Circ. - 2007. - Vol. 16. - P. 28-30.

3. Annes J., Munger J., Rifkin D. Making sense of latent TGF-beta activation // J. Cell. Sci. - 2003. - Vol. 116. - P. 217-224.

4. Blobe G., Schiemann W., Lodish H. Role of transforming growth factor beta in human disease // N. Engl. J. Med. - 2000. - Vol. 342. - P. 1350-1358.

5. Byers P. Determination of the molecular basis of Marfan syndrome: a growth industry // J. Clin. Invest. - 2004. - Vol. 114. - P. 161-163.

6. Chung A., Yang H., Radomski M. et al. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9 // Circ. Res. - 2008. - Vol. 102. - P. e73-85.

7. Collod-Béroud G., Le Bourdelles S., Ades L. et al. Databases. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database // Human mutation. - 2003. - Vol. 22. - P. 199-208.

8. Corson G., Charbonneau N., Keene D. et al. Differential expression of fibrillin-3 adds to microfibril variety in human and avian, but not rodent, connective tissues // Genomics. - 2004. - Vol. 83. - P. 461-472.

9. Coucke P., Willaert A., Wessels M. et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome // Nat. Genet. - 2006. - Vol. 38. - P. 452-457.

10. Cushing M., D. Mariner P., Liao J.-T. et al. Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells // FASEB J. - 2008. - Vol. 22. - P. 1769-1777.

11. De Paepe A., Devereux R., Dietz H. et al. Revised diagnostic criteria for the Marfan syndrome // Am. J. Med. Genet. - 1996. - Vol. 62. - P. 417-426.

12. Faivre L., Collod-Beroud G., Child A. et al. Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies an international study of 1009 probands // J. Med. Genet. - 2008. - Vol. 45. - P. 384-390.

13. Gelb B. Marfan's syndrome and related disorders - more tightly connected than we thought // N. Engl. J. Med. - 2006. - Vol. 355. - P. 841-844.

14. Grainger D., Witchell C., Metcalfe J. Tamoxifen elevates transforming growth factor-ß and suppresses diet-induced formation of lipid lesions in mouse aorta // Nat. Med. - 1995. - Vol. 1. - P. 1067-1073.

15. Habashi J., Judge D., Holm T. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome // Science. - 2006. - Vol. 312. - P. 117-121.

16. Hollister D., Godfrey M., Sakai L. et al. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome // N. Engl. J. Med. - 1990. - Vol. 323. - P. 152-159.

17. Judge D., Dietz H. Marfan's syndrome // Lancet. - 2005. - Vol. 366. - P. 1965-1976.

18. Lee B., Godfrey M., Vitale E. et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes // Nature. - 1991. - Vol. 352. - P. 330-334.

19. Li B., Khanna A., Sharma V. et al. TGF-ß1 DNA polymorphisms, protein levels, and blood pressure // Hypertension. - 1999. - Vol. 33. - P. 271-275.

20. Loeys B., Chen J., Neptune E. et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 // Nat. Genet. - 2005. - Vol. 37. - P. 275-281.

21. Mizuguchi T., Collod-Beroud G., Akiyama T. et al. Heterozygous TGFBR2 mutations in Marfan syndrome // Nat. Genet. - 2004. - Vol. 36. - P. 855-860.

22. Neptune E., Frischmeyer P., Arking D. et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome // Nat. Genet. - 2003. - Vol. 33. - P. 407-411.

23. Ng C., Cheng A., Myers L. et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome // J. Clin. Invest. - 2004. - Vol. 114. - P. 1586-1592.

24. Pannu H., Fadulu V., Chang J. et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections // Circulation. - 2005. - Vol. 112. - P. 513-520.

25. Pearson G., Devereux R., Loeys B. et al. Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on Research in Marfan Syndrome and Related Disorders // Circulation. - 2008. - Vol. 118. - P. 785-791.

26. Putnam E., Zhang H., Ramirez F. et al. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly // Nat. Genet. - 1995. - Vol. 11. - P. 456-458.

27. Pyeritz R. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy // Heart. - 2009. - Vol. 95. - P. 173-175.

28. Pyeritz R. Small molecule for a large disease // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2829-2831.

29. Rifkin D. Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability // J. Biol. Chem. - 2005. - Vol. 280. - P. 7409-7412.

30. Robinson P., Arteaga-Solis E., Baldock C. et al. The molecular genetics of Marfan syndrome and related disorders // J. Med. Genetics. - 2006. - Vol. 43. - P. 769-787.

31. Robinson P., Booms P., Katzke S. et al. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies // Hum. Mut. - 2002. - Vol. 20. - P. 153-161.

32. Saharinen J., Keski-Oja J. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta // Mol. Biol. Cell. - 2000. - Vol. 11. - P. 2691-2704.

33. Yamada Y., Miyauchi A., Goto J. et al. Association of a polymorphism of the transforming growth factor-ß1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women // J. Bone Miner. Res. - 1998. - Vol. 13. - P. 1569-1576.